Core Viewpoint - As of April 28, 2025, Kangtong Medical (301515) closed at 17.78 yuan, down 0.61%, with a trading volume of 8611 lots and a transaction amount of 15.2042 million yuan [1] Group 1: Financial Performance - Kangtong Medical reported a main revenue of 24.2867 million yuan for Q1 2025, a year-on-year decrease of 68.09% [2] - The net profit attributable to the parent company was 1.579 million yuan, down 85.25% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 1.4143 million yuan, a decline of 86.46% year-on-year [2] - The company's debt ratio stands at 36.26% with financial expenses of -515,200 yuan and a gross profit margin of 36.15% [2] Group 2: Market Position and Valuation - Kangtong Medical's total market value is 1.778 billion yuan, significantly lower than the industry average of 9.941 billion yuan, ranking 109 out of 122 in the medical device industry [2] - The company's net assets are 1.248 billion yuan, compared to the industry average of 3.91 billion yuan, ranking 97 out of 122 [2] - The price-to-earnings ratio (P/E) is 281.52, much higher than the industry average of 44.38, ranking 93 out of 122 [2] - The price-to-book ratio (P/B) is 1.43, lower than the industry average of 2.76, ranking 29 out of 122 [2] - The gross margin is 36.15%, below the industry average of 51.86%, ranking 96 out of 122 [2] - The net margin is 6.5%, compared to the industry average of 9.77%, ranking 82 out of 122 [2] - The return on equity (ROE) is 0.12%, significantly lower than the industry average of 1.32%, ranking 97 out of 122 [2]
股票行情快报：港通医疗（301515）4月28日主力资金净买入158.81万元